NEW YORK, Sept. 16, 2022 (GLOBE NEWSWIRE) — Bragar Eagel & Squire, PC, a nationally recognized shareholder rights law firm, is investigating potential claims against Corcept Therapeutics, Inc. (NASDAQ: CORT), Discover Financial Services (NYSE : DFS ), Mercury Systems, Inc. (NASDAQ: MRCY) and Fulgent Genetics, Inc. (NASDAQ: FLGT). Our investigations address whether these companies have violated federal securities laws and/or engaged in other illegal business practices. For more information on each case, see the link provided.

Corcept Therapeutics, Inc. (NASDAQ:CORT)

On December 8, 2021, Corcept announced in a filing with the US Securities and Exchange Commission that “[o]On November 15, 2021, the Company received a subpoena under Section 248 of the Health Insurance Portability and Accountability Act of 1996 (HIPAA) from the United States Attorney for the District of New Jersey (the “NJ USAO”) requesting information regarding the sales and promotions of Korlym, Corcept’s relationships with and payments to healthcare professionals who may prescribe or recommend Korlym, and prior approvals and reimbursements for Korlym.” Corcept further announced that “[t]The NJ USAO has notified Corcept that it is investigating whether any criminal or civil violations by Corcept have occurred in connection with the matters identified in the subpoena.”

As a result of this news, Corcept’s stock price fell $3.71 per share, or 16.91%, to close at $18.23 per share on December 8, 2021.

For more information on the Corcept investigation, visit: https://bespc.com/cases/CORT

Discover Financial Services (NYSE:DFS)

Discover is a digital banking and payment services company that offers credit card loans, personal student loans, personal loans, home loans, and deposit products to its customers.

In 2015, the US Consumer Financial Protection Bureau (“CFPB”) issued a consent order against Discover based on the CFPB’s finding that Discover to…